Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, Sweden - May 9, 2025 - Biosergen AB ("Biosergen" or the "Company"), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the proposal of electing Dr. Marco Taglietti, M.D., as a new member of the Board of Directors ahead of the upcoming Annual General Meeting.
The proposal is made in light of the Company's continued promising clinical development of its antifungal drug candidate, BSG005, which is currently being investigated in a proof-of-concept trial as a rescue therapy for patients who have failed previous standard-of-care antifungal treatments.
"We are very pleased that Dr. Taglietti has agreed to make himself available as a new member of the Board of Directors at Biosergen. His extensive and successful track record in anti-infective drug development, securing regulatory approvals for multiple therapies, and experience with significant licensing deals aligns well with Biosergen's current stage and strategic direction," says Anna Ljung, Chairperson of the Board. "In particular, his recent experience as CEO and director of the US-listed biotech SCYNEXIS that successfully out-licensed rights for a novel antifungal drug to a major pharmaceutical company, GSK, is highly relevant to our ongoing development of BSG005."
Dr. Taglietti previously served as President and CEO of SCYNEXIS, Inc. (Nasdaq: SCYX) from 2015 to 2022, where he led the company's lead antifungal compound, ibrexafungerp, from Phase 1 trials through FDA approval, U.S. commercial launch and successful global out-licensing deals. Ibrexafungerp, a novel triterpenoid antifungal, was licensed to GSK for USD 90 million in upfront payments and up to USD 503 million in potential milestones and royalties for international rights, fand to Hansoh Pharma for USD 10 million upfront for the Chinese market, with an additional USD 112 million in milestones and royalties. Currently, Dr. Taglietti is Chief Executive Officer of NanoNewron, a private biotechnology company developing novel therapies for neurodegenerative diseases using proprietary nanobody technology to deliver biologics across the blood-brain barrier. Dr. Taglietti currently serves on the boards of US-listed Aquestive Therapeutics (Nasdaq AQST) and privately held Aurobac Therapeutics, a company developing novel treatments for drug-resistant bacterial infections.
Earlier in his career, Dr. Taglietti held senior executive roles at Forest Laboratories, Stiefel Laboratories, and Schering-Plough Research Institute. He has overseen the development and market introduction of more than 30 pharmaceutical products across multiple therapeutic areas, including several anti-infective therapies, among them antifungals.
Dr. Taglietti holds a medical degree and a board certification in Infectious Diseases, both from the University of Pavia, Italy.
If elected, Dr. Taglietti would join the current Board members-Deputy Chairperson Marianne Kock, Mattias Klintemar, and Robert Molander-alongside Chairperson Anna Ljung. All current members have agreed to stand for re-election.
The Board's full proposal will be included in the notice of Biosergen's Annual General Meeting and made available on the Company's website: www.biosergen.net.